20 news items
Candel Reports Upbeat Data From Lung Cancer Study
CADL
KRYS
MRNS
24 May 24
), together with standard of care (SoC) in patients with stage III/IV non-small cell lung cancer (NSCLC) who are non-responsive to immune checkpoint
Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
AKAN
AKTS
BIOR
24 May 24
for Advanced Non-Small Cell Lung Cancer (NSCLC) in patients non-responsive to Immune Checkpoint Inhibitor (ICI) treatment at 2024 ASCO Annual Meeting
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
CADL
23 May 24
CAN-2409 treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates
AZN
CADL
LTRN
23 May 24
. There is optimism within the Oncolytics team that improved response rates from the mFOLFIRINOX combination, compared
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates
AZN
CADL
LTRN
23 May 24
within the Oncolytics team that improved response rates from the mFOLFIRINOX combination, compared
p6jmtck1y51x2rg592dw35jtn009oahswchx7 sdhu4tpqklg
CADL
20 May 24
-tumor immune response. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells
fu8lh9qar7ir925q ek7mw7b45t6qmg6til3kafxtdt4ysn3o9z
ABVC
AMGN
CADL
15 May 24
combination demonstrates improvements in response rate over historical control trials, this treatment approach could move forward to a registration-enabling
5o2mk6w12pylheaky4oy0qq1wpnksqbe2c5
ABVC
AMGN
CADL
15 May 24
demonstrates improvements in response rate over historical control trials, this treatment approach could move forward to a registration-enabling study
hhga09ps0meqvp20dhg2if2ef6vizt3bybahgjmz7v3858el5dx5zag
AZN
CADL
HALO
9 May 24
."
Notably, Oncolytics plans to evaluate the correlation between tumor responses and the expansion of tumor
gjqug5zu6nvn4hsg60ullaprq08mb63ib3jmmr6xxqx
AZN
CADL
HALO
9 May 24
."
Notably, Oncolytics plans to evaluate the correlation between tumor responses and the expansion
a17tj9v28r0myhgh1676vnhk02xtphwst
AZN
CADL
HALO
9 May 24
, Oncolytics plans to evaluate the correlation between tumor responses and the expansion of tumor-infiltrating lymphocytes (TILs
i186yx58mfcwy0gv mnlij8
AZN
CADL
HALO
9 May 24
, Oncolytics plans to evaluate the correlation between tumor responses and the expansion of tumor-infiltrating lymphocytes (TILs
15fti9yzuw9s0eafyi8ah1pwy8gxu7o
CADL
11 Apr 24
the activation of a robust systemic anti-tumor immune response.About Orphan Drug DesignationOrphan Drug Designation is granted
r6i1oqy8tp0ib3mk7hwseaafcra
CADL
9 Apr 24
Analytics suite, was shown to induce tertiary lymphoid structure formation, inhibit tumor growth, and improve response to immune checkpoint inhibitor
z2wwgptp49tppc9s63fpfk3lef448
CADL
4 Apr 24
).
Previous analysis of blood and resected tumors showed consistent and robust activation of the immune response after experimental treatment
llxwkm24aaazruz154qi75s1a0gi4uzurqbj3cfcl9iwjr
CADL
4 Apr 24
response NEEDHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company
n04l5num6r5zvwkws8aj51osbp61d5szwjvtk e0qmdwqn3ramx25vlxd62b
CADL
1 Apr 24
condition.
Positive HSV-1 serology was a predictor of response and was associated with improved survival (mOS in this population reached
tv40hji9 m0oo5xia4wr5knrahr1pm9k9mdc3pbf
CADL
28 Mar 24
of immune response after dosing of CAN-2409, and a favorable tolerability profile.U.S. Food and Drug Administration (FDA
oiyc8yexo6 ukgfyv32a6qrwl830coxi4nwf7zq
CADL
15 Mar 24
that this tactic has been shown to produce an individualized immune response specific to the patient and their cancer
wzo8q180h0z8lhqkcgsyy3d41waij00 4lzapz8hi8if918
CADL
5 Mar 24
response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel
- Prev
- 1
- Next